Gene expression differences of mammary tumors after treatment

Current therapeutic outcomes for breast cancer underscore the complexity of treating a heterogeneous disease. Indeed, studies have shown that differences in gene expression among patients with the same subtype of breast cancer are correlated with the response to treatment. This strongly suggests that there is an urgent need to treat breast cancer with a personalized approach. Here we employed cell signaling pathway signatures predict pathway activity in subtypes of MMTV-Myc mammary tumors. We then split tumors into subsets and developed individualized combinatorial treatments for two subtypes with distinct pathway activation patterns. In this treatment, we focus on papillary subtype-specific treatment, targeting Myc, Stat3, and Akt pathways. We compared gene expression differences after treatment. Tumor mice receiving vehicle- or drug-treatment for 21 days. Total RNA was collected. 3 for vehicle treatment. 3 for drug treatment.